NCT00748839

Heparin-Induced Thrombocytopenia: Development and Validation of a Predictive Clinical

Heparin-Induced Thrombocytopenia : Development and Validation of a Predictive Clinical Score: a Prospective Multicenter Study Under the Auspices of the French Haemostasis and Thrombosis Study Group (GEHT)in Cooperation With the French Association of Regional PharmacoVigilance Center (AFCRPV)

• Status: Completed
• Phase: —
• Study type: Observational
• Enrollment: 2,700 (actual)
• Sponsor: Centre Hospitalier Universitaire de Saint Etienne · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

Although Heparin-induced thrombocytopenia (HIT) is a rare complication of heparin treatment, it results in a high rate of morbidity and mortality, the cumulative rate of thrombosis recurrence, amputation and death approaching 52 % at one month if no specific treatment is initiated. It is therefore vital to diagnose HIT as early and as reliably as possible to permit appropriate management of this rare condition. During the acute phase of HIT, clinicians and biologists can only suspect this complication with a greater or lesser degree of confidence. Clinical data are not sufficiently sensitive or specific to confirm or refute thr diagnosis of HIT.

Detailed description

Purpose : To create and validate a score predicting the diagnosis of HIT

Conditions

• Heparin-induced Thrombocytopenia

Timeline

• Start date: 2009-03-01
• Primary completion: 2012-11-01
• Completion: 2012-11-01
• First posted: 2008-09-09
• Last updated: 2012-11-27

Locations

27 sites across 1 country: France